Transcenta Holding Limited (6628.HK)
6628.HK Stock Price Chart
Explore Transcenta Holding Limited interactive price chart. Choose custom timeframes to analyze 6628.HK price movements and trends.
6628.HK Company Profile
Discover essential business fundamentals and corporate details for Transcenta Holding Limited (6628.HK) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
29 Sept 2021
Employees
184.00
Website
https://www.transcenta.comCEO
Xueming Qian
Description
Transcenta Holding Limited, a clinical stage biopharmaceutical company, engages in the discovery, research, development, manufacture, and commercialization of various drugs in the People's Republic of China and the United States. The company develops MSB2311, a humanized PD-L1 monoclonal antibody (mAb) candidate for TMB-H solid tumors; TST001, a humanized claudin 18.2 mAb candidate for solid tumors, such as gastric cancer and is under Phase II clinical trial; TST005, a PD-L1/TGF-ß bi-functional antibody candidate which is under Phase Ia clinical trial for solid tumors, including certain lung cancers; TST010, an antibody candidate targeting regulatory T cells to enhance T cell mediated tumor killing;TST002 (Blosozumab), a humanized sclerostin mAb candidate for osteoporosis; and TST004, a humanized mannan-binding lectin serine protease 2 (MASP 2) mAb candidate for IgA kidney diseases. It also develops TST003, an antibody candidate targeting a novel immune regulatory protein produced by tumor-associated fibroblasts or tumor cells with mesenchymal phenotype; TST006, a bi-specific claudin 18.2/PD-L1 antibody; TST008, a tri-functional antibody combining a MASP2 antibody fused with a truncated transmembrane activator and CAML interactor protein; MSB0254, a humanized VEGFR-2 mAb candidate for solid tumors and is under Phase Ib/IIa clinical trials; and MSB2311, A humanized PD-L1 mAb Candidate for solid tumors and is under Phase Ib/IIa clinical trials Transcenta Holding Limited has collaboration agreements with Eli Lilly and Company, Alebund Pharmaceuticals, and Merck. The company was formerly known as MabSpace International Limited and changed its name to Transcenta Holding Limited in June 2019. Transcenta Holding Limited was incorporated in 2010 and is headquartered in Suzhou, the People's Republic of China.
6628.HK Financial Timeline
Browse a chronological timeline of Transcenta Holding Limited corporate events including earnings releases, dividend announcements, and stock splits.
Earnings released on 27 Aug 2025
EPS came in at -$0.29 , while revenue for the quarter reached $2.96M .
Earnings released on 31 Dec 2024
EPS came in at -$0.21 surpassing the estimated -$0.31 by +34.35%, while revenue for the quarter reached $3.56M , missing expectations by -97.56%.
Earnings released on 30 Sept 2024
EPS came in at -$0.21 , while revenue for the quarter reached $3.71M .
Earnings released on 29 Aug 2024
EPS came in at -$0.18 surpassing the estimated -$0.50 by +64.46%, while revenue for the quarter reached $2.45M , missing expectations by -91.51%.
Earnings released on 7 Jun 2024
EPS came in at -$0.18 , while revenue for the quarter reached $2.47M .
Earnings released on 28 Mar 2024
EPS came in at -$0.31 surpassing the estimated -$0.55 by +44.14%, while revenue for the quarter reached $9.83M , missing expectations by -89.39%.
Earnings released on 25 Mar 2024
EPS came in at -$0.30 , while revenue for the quarter reached $9.53M .
Earnings released on 22 Aug 2023
EPS came in at -$0.32 surpassing the estimated -$0.53 by +40.02%, while revenue for the quarter reached $19.51M , missing expectations by -68.96%.
Earnings released on 31 Mar 2023
EPS came in at -$0.27 , while revenue for the quarter reached $45.63M , beating expectations by +54.45%.
Earnings released on 31 Mar 2023
EPS came in at -$0.33 , while revenue for the quarter reached $20.59M .
Earnings released on 30 Sept 2022
EPS came in at -$0.26 , while revenue for the quarter reached $44.01M .
Earnings released on 29 Aug 2022
EPS came in at -$0.29 , while revenue for the quarter reached $13.41M .
Earnings released on 30 Jun 2022
EPS came in at -$0.27 , while revenue for the quarter reached $12.74M .
Earnings released on 21 Mar 2022
EPS came in at -$1.64 , while revenue for the quarter reached $14.42M .
Earnings released on 30 Sept 2021
EPS came in at -$1.61 , while revenue for the quarter reached $14.21M .
Earnings released on 29 Sept 2021
EPS came in at -$2.49 , while revenue for the quarter reached $22.57M .
Earnings released on 14 Sept 2021
EPS came in at -$0.19 , while revenue for the quarter reached $9.33M .
Earnings released on 31 Dec 2020
EPS came in at -$1.62 , while revenue for the quarter reached $31.28M .
Earnings released on 30 Sept 2020
EPS came in at -$1.55 , while revenue for the quarter reached $30.03M .
6628.HK Stock Performance
Access detailed 6628.HK performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.